With the CRL behind us, the next major move is going to be the upcoming downward movement upon a discounted and dilutive financing. CEO is in NY this week looking to raise money. PFE-related money is tied to milestones which PLX failed to achieve, and anyone suggesting PFE will somehow put money in outside of that doesn't have a clue as to biotech deal structures. Despite the CEOs "forward-looking" comments, PLX has only enough cash to get through September at the latest. Just wait until they disclose their increased burn rate and longer time frame to next FDA decision.
While I feel bad for those who went off the cliff, it does give satisfaction seeing the chronic posters (esp. Oteensdad) who incessantly touted yet disparaged other viewpoints to publicly eat crow. Many of these will come back with new screen names after losing all credibility the way they did. I know the aforementioned little Israeli reads my posts and will undoubtedly want to continue spouting his garbage. Paid company shill I doubt, though obviously a misguided and non-critical biotech observer who fancies himself a know-it-all. Must have felt great getting bent over by his own people who he so loudly supported.
Those who want to be long should wait until a financing is completed, otherwise they will get punished again.